Form D · Biotechnology

Lysosomal Therapeutics, Inc.

Cambridge, MA · CIK 0001607854

Offering snapshot reported Nov 7, 2019 · SEC filing

Reported sold
$1M
Offering amount: $3M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 25, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 7, 2019Initial$1,000,000No comparison10SEC filing
Jan 18, 2017Amendment$26,124,936$16,124,934vs Feb 11, 20159SEC filing
Oct 6, 2016Initial$6,000,000No comparison9SEC filing
Feb 11, 2015Initial$10,000,002No comparison9SEC filing
May 13, 2014Initial$4,842,033No comparison11SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-352903

Source: Form D, filed Nov 7, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Cornelis Been Director, Executive
Bruce L. Booth Director
Robert Carpenter Director, Executive
Bernard Davitian Director
Daniel Geffken Executive
Steven E. Hall Director
Dimitri Krainc Director
Carole Neuchterlein Director
Carole Nuechterlein Director
Henri Termeer Director
Clay Thorp Director
Peter Wirth Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
19 Blackstone Street
Cambridge, MA, 02139